Assembly Biosciences: Strong Clinical Execution and Strategic Partnerships Drive Buy Rating
Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Assembly Biosciences with a $50 target, citing strong clinical execution in HSV, HDV, and HBV areas. Key developments include ABI-5366's success in HSV trials and promising results for ABI-6250 in HDV. The strategic partnership with Gilead Sciences enhances Assembly's position. Guggenheim also reiterated a Buy rating with a $39 target. Trucchio is a top analyst with a 34.8% average return.
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Assembly Biosciences, with a price target of $50.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Assembly Biosciences’ strong clinical execution across its key therapeutic areas, including HSV, HDV, and HBV. The company has shown significant progress in its clinical trials, with its lead oral helicase-primase inhibitor, ABI-5366, achieving notable reductions in viral shedding and lesion rates in recurrent genital HSV infection. Additionally, the oral NTCP inhibitor ABI-6250 has demonstrated promising results in HDV, confirming target engagement and safety, which sets the stage for Phase 2 trials in 2026.
Furthermore, Assembly’s next-generation oral capsid-assembly modulator, ABI-4334, has shown robust antiviral activity and safety in HBV trials, reinforcing its potential role in curative regimens. The strategic partnership with Gilead Sciences further strengthens Assembly’s position, providing opt-in options, milestone funding, and a profit-sharing structure. With upcoming data releases and protocol submissions expected, Assembly Biosciences is well-positioned for multiple significant catalysts in 2026, supporting the Buy rating and a target price of $50 per share.
According to TipRanks, Trucchio is a top 100 analyst with an average return of 34.8% and a 52.26% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Aligos Therapeutics, Precision BioSciences, and Altimmune.
In another report released on November 11, Guggenheim also reiterated a Buy rating on the stock with a $39.00 price target.
